Basit öğe kaydını göster

dc.contributor.authorKurtipek, Ercan
dc.contributor.authorCayci, Mustafa
dc.contributor.authorDuzgun, Nuri
dc.contributor.authorEsme, Hidir
dc.contributor.authorTerzi, Yuksel
dc.contributor.authorBakdik, Suleyman
dc.contributor.authorBekci, Taha Tahir
dc.date.accessioned2020-06-21T13:46:28Z
dc.date.available2020-06-21T13:46:28Z
dc.date.issued2015
dc.identifier.issn0363-9762
dc.identifier.issn1536-0229
dc.identifier.urihttps://hdl.handle.net/20.500.12712/14306
dc.descriptionWOS: 000354883000015en_US
dc.descriptionPubMed: 25742234en_US
dc.description.abstractObjective: The study was designed to determine the relationship between survival time of standardized uptake value (SUVmax and SUVmean) andmetabolic tumor volume (MTV) in patients with non-small cell lung cancer (NSCLC), and examine the impact of demographic, clinical, and radiological data of these patients on survival. Materials and Methods: We performed a retrospective analysis of the records of 79 patients with NSCLC who presented to our hospital between May 2010 and March 2013, received a final diagnosis, and underwent F-18-FDG PET/CT for staging. Clinical, radiological, and F-18-FDG PET/CT parameters with an impact on prognosis such as the SUVmax of the primary tumor as calculated by the volumetric region of interest in the F-18-FDG PET/CT scans during initial diagnosis, mean SUV of the tumor, and MTV obtained with a threshold of SUVmax greater than 2.5 were recorded and statistically analyzed. A statistical analysis was carried out based on the clinical, radiological, and PET/CT findings of the patients who were divided into 2 groups: survivors and nonsurvivors. Results: Seventy patients (88.6%) were men, and 9 (11.4%) were women. The mean age was 63.65 +/- 11.51 years in the nonsurvivor group (n = 40) versus 62.74 +/- 10.60 years in the survivor group (n = 39) (Table 1). The mean survival time from diagnosis was 7.9 +/- 6.52 months in the nonsurvivor group versus 14.09 +/- 7.41 months in the survivor group. The mean survival time was 12.9 +/- 7.9 months for those aged 60 or younger, whereas it was 9.9 +/- 7.2 years for those aged 60 or older. According to the Cox regression analysis, higher MTV [relative risk (RR), 1.006; P = 0.03] and mean SUVmax (mSUV) (RR, 1.302; P = 0.03) had a significant impact on shortening of the mean survival time. However, no statistical significance was reached for SUVmax measurements (RR, 0.970; P = 0.39). Furthermore, there was a significant relationship between increased tumor size (<2 cm, 2-4 cm, and = 4 cm) and shortened mean survival time (P = 0.03). Conclusion: The present study showed that MTV and mSUVof FDG PET/CT scans of the tumor, but not SUVmax, had a significant impact on survival time of patients with NSCLC. Based on this result, we believe that we might have more accurate information about the survival time of our patients if we also evaluate mSUV and MTV in combination with mSUV, which is frequently used for diagnosis and monitoring of patients with NSCLC during our daily practice.en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectF-18-fluorodeoxyglucose (FDG)en_US
dc.subjectmetabolic tumor volumeen_US
dc.subjectnon-small cell lung canceren_US
dc.titleF-18-FDG PET/CT Mean SUV and Metabolic Tumor Volume for Mean Survival Time in Non-Small Cell Lung Canceren_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume40en_US
dc.identifier.issue6en_US
dc.identifier.startpage459en_US
dc.identifier.endpage463en_US
dc.relation.journalClinical Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster